mitoxantrone has been researched along with Leukocytopenia in 65 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficiency of mitoxantrone in multiple sclerosis." | 9.08 | Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. ( Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997) |
| "Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule." | 9.06 | Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988) |
| "Mitoxantrone (Novantrone; dihydroxyanthracenedione) is an anthraquinone previously shown to be active in human breast cancer." | 9.05 | A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. ( Allegra, JC; Bryan, S; Dukart, G; Henderson, IC; Reisman, A; Woodcock, T; Woolf, S, 1985) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 9.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| "To evaluate the efficacy and safety of mitoxantrone hydrochloride and determine how it exhibits a differential inhibitory effect on subsets of B cells in patients with highly relapsing neuromyelitis optica (NMO)." | 7.77 | Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. ( Kim, HJ; Kim, SH; Kim, W; Li, XF; Park, MS; Sohn, EH, 2011) |
| "46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks." | 7.68 | Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. ( Dalesio, O; Giaccone, G; Kirkpatrick, A; Mattson, K; Planteydt, HT; van Breukelen, FJ; van Zandwijk, N, 1991) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 7.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks." | 7.67 | Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. ( Alberts, DS; Balcerzak, SP; Bonnet, JD; Stephens, RL, 1985) |
| "Twenty-eight patients with advanced breast cancer who had no prior chemotherapy received 14 mg/m2 of mitoxantrone iv on Day 1 and 600 mg/m2 of cyclophosphamide on Day 2, repeated every 4 weeks." | 7.67 | Mitoxantrone and cyclophosphamide in patients with advanced breast cancer. ( Ehninger, G; Heidemann, EG; Waller, HD; Weible, KH, 1984) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 6.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Leukopenia is similar with the three drugs." | 6.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "To evaluate the efficiency of mitoxantrone in multiple sclerosis." | 5.08 | Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. ( Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997) |
| "Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule." | 5.06 | Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988) |
| "Mitoxantrone (Novantrone; dihydroxyanthracenedione) is an anthraquinone previously shown to be active in human breast cancer." | 5.05 | A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. ( Allegra, JC; Bryan, S; Dukart, G; Henderson, IC; Reisman, A; Woodcock, T; Woolf, S, 1985) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 5.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| "To evaluate the efficacy and safety of mitoxantrone hydrochloride and determine how it exhibits a differential inhibitory effect on subsets of B cells in patients with highly relapsing neuromyelitis optica (NMO)." | 3.77 | Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. ( Kim, HJ; Kim, SH; Kim, W; Li, XF; Park, MS; Sohn, EH, 2011) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 3.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)." | 3.68 | [Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991) |
| "28 patients (26 with breast cancer and 2 with colon cancer) received mitomycin, mitoxantrone and methotrexate (MMM)." | 3.68 | Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate. ( Blomqvist, CP; Muhonen, TT; Pyrhönen, SO; Wiklund, TA, 1992) |
| "46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks." | 3.68 | Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. ( Dalesio, O; Giaccone, G; Kirkpatrick, A; Mattson, K; Planteydt, HT; van Breukelen, FJ; van Zandwijk, N, 1991) |
| "Twenty-eight patients with advanced breast cancer who had no prior chemotherapy received 14 mg/m2 of mitoxantrone iv on Day 1 and 600 mg/m2 of cyclophosphamide on Day 2, repeated every 4 weeks." | 3.67 | Mitoxantrone and cyclophosphamide in patients with advanced breast cancer. ( Ehninger, G; Heidemann, EG; Waller, HD; Weible, KH, 1984) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Mitoxantrone, an anthracenedione derivative, was administered by members of the Southwest Oncology Group to thirty patients with metastatic malignant melanoma." | 3.67 | Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot. ( Costanzi, JJ; Taylor, SA; Tranum, BT; Von Hoff, DD, 1985) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks." | 3.67 | Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. ( Alberts, DS; Balcerzak, SP; Bonnet, JD; Stephens, RL, 1985) |
| " Samples for pharmacokinetic studies were collected." | 2.79 | Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. ( Du, P; Gui, L; Han, X; Li, C; Li, N; Liu, P; Shi, Y; Song, Y; Yang, J; Zhang, S; Zhao, X, 2014) |
| "Mitoxantrone has shown moderate activity in advanced epithelial ovarian cancer following intermittent i." | 2.68 | Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer. ( Aversa, S; Azzoni, P; Endrizzi, L; Fiorentino, MV; Koussis, H; Nicoletto, MO; Padrini, R; Palumbo, M; Rosabian, A, 1995) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 2.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| " every 3 weeks in escalating doses combined with a fixed dose of s." | 2.67 | Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. ( Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F; Von Hoff, DD, 1991) |
| "Objective response rates were 21% in breast cancer, 36% in non-Hodgkin's lymphoma, 56% in acute lymphocytic leukemia, 14% in acute nonlymphocytic leukemia, 31% in gastric cancer and 5% in primary hepatic cancer." | 2.66 | [Phase II clinical trial on mitoxantrone]. ( Gao, HR, 1989) |
| "Leukopenia is similar with the three drugs." | 2.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Twenty-six evaluable patients with advanced or recurrent squamous cell carcinoma of the uterine cervix were treated with mitoxantrone at a dosage of 12 mg/m2 every 3 weeks." | 2.66 | Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group. ( Bundy, B; Hatch, KD; Muss, HB; Sutton, GP, 1985) |
| "Usually, thrombocytopenia was not associated with bleeding manifestations." | 2.45 | Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. ( Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O, 2009) |
| "As no data on this topic exist for MALT lymphoma, we have retrospectively analysed our experience with R plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone (R-CHOP/R-CNOP) in patients with relapsed MALT lymphoma." | 1.33 | Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. ( Chott, A; Drach, J; Jager, U; Puspok, A; Raderer, M; Streubel, B; Troch, M; Turetschek, K; Wohrer, S; Zielinski, CC, 2006) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| " A dose-response relationship characterized body-weight loss and survival rate." | 1.29 | Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics. ( Bizi, E; Hallek, M; Lemaigre, G; Lévi, F; Metzger, G; Tampellini, M, 1994) |
| "Thirty-four adults with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside (ara-C) 3 g/m2 intravenously over 2 hours every 12 hours for six doses, followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) 125 microgram/m2 intravenously over 4 hours daily until recovery of granulocytes above 2." | 1.28 | Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. ( Anaissie, E; Beran, M; Estey, EH; Gutterman, J; Kantarjian, HM; Keating, MJ; O'Brien, S; Rios, MB, 1992) |
| "In the 16 patients with squamous cell carcinoma that could be evaluated for response, one had a partial response lasting 8 months, and six had stable disease." | 1.28 | Phase II trial of mitoxantrone in head and neck carcinoma. ( Ardalan, B; Benedetto, P; Desai, P; Feun, LG; Hussein, AM; Richman, SP; Savaraj, N; Sridhar, KS; Waldman, SM, 1991) |
| "Thirty-three patients with advanced cancer received the drug on a daily X 5 schedule." | 1.27 | Phase I study of mitoxantrone on a daily X 5 schedule. ( Goldsmith, MA; Greenspan, EM; Holland, JF; Jaffrey, IH; Ohnuma, T, 1984) |
| "Twenty-six evaluable patients with advanced epithelial ovarian cancer were treated with mitoxantrone at a dosage of 12 mg/m2 every three weeks." | 1.27 | Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. ( Asbury, R; Bundy, B; Ehrlich, CE; Graham, J; Muss, HB, 1984) |
| "Thirty-seven patients with metastatic prostate cancer refractory to endocrine therapy were treated in a phase II trial of mitoxantrone." | 1.27 | Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. ( Crawford, ED; Drelichman, A; Osborne, CK; Von Hoff, DD, 1983) |
| "Mitoxantrone (DAD) is a new agent which intercalates into DNA." | 1.27 | Phase I trial of mitoxantrone by 24-hour continuous infusion. ( Anderson, KC; Canellos, GP; Cohen, GI; Frei, E; Garnick, MB; Israel, M; Meshad, MW; Modest, E; Pegg, WJ, 1983) |
| "Thirty-five patients with hepatocellular carcinoma (HCC) have been treated with the Anthracenedione derivative, Mitozantrone." | 1.27 | Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. ( Dunk, AA; Johnson, PJ; Lok, AS; Melia, W; Murray-Lyon, I; Scott, SC; Thomas, HC; Williams, R, 1985) |
| "Mitoxantrone was administered by intravenous drip infusion of 12 mg/m2 every three weeks." | 1.27 | Phase II study of mitoxantrone in patients with non-small cell lung cancer. ( Eguchi, K; Hoshi, A; Saijo, N; Sakurai, M; Sano, T; Sasaki, Y; Shinkai, T; Suga, J; Tamura, T, 1986) |
| "Leukopenia was the dose-limiting toxic effect and thrombocytopenia was mild." | 1.26 | Clinical and clinical pharmacologic studies of mitoxantrone. ( Krakoff, IH; McCormack, JJ; Stewart, JA, 1982) |
| "Leukopenia was the dose-limiting toxic effect." | 1.26 | Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. ( Alberts, DS; Goodman, GE; Griffith, KS; Herman, TS; Murray, E, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (49.23) | 18.7374 |
| 1990's | 26 (40.00) | 18.2507 |
| 2000's | 4 (6.15) | 29.6817 |
| 2010's | 3 (4.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enriquez, CAG | 1 |
| Espiritu, AI | 1 |
| Pasco, PMD | 1 |
| Yang, J | 1 |
| Shi, Y | 1 |
| Li, C | 1 |
| Gui, L | 1 |
| Zhao, X | 1 |
| Liu, P | 1 |
| Han, X | 1 |
| Song, Y | 1 |
| Li, N | 1 |
| Du, P | 1 |
| Zhang, S | 1 |
| Ram, R | 1 |
| Bonstein, L | 1 |
| Gafter-Gvili, A | 1 |
| Ben-Bassat, I | 1 |
| Shpilberg, O | 1 |
| Raanani, P | 1 |
| Sharma, R | 1 |
| Cunningham, D | 1 |
| Smith, P | 1 |
| Robertson, G | 1 |
| Dent, O | 1 |
| Clarke, SJ | 1 |
| Kim, SH | 1 |
| Kim, W | 1 |
| Park, MS | 1 |
| Sohn, EH | 1 |
| Li, XF | 1 |
| Kim, HJ | 1 |
| Enschede, SH | 1 |
| Porter, C | 1 |
| Venugopal, P | 1 |
| Gregory, SA | 1 |
| Raderer, M | 1 |
| Wohrer, S | 1 |
| Streubel, B | 1 |
| Drach, J | 1 |
| Jager, U | 1 |
| Turetschek, K | 1 |
| Troch, M | 1 |
| Puspok, A | 1 |
| Zielinski, CC | 1 |
| Chott, A | 1 |
| Hilgers, RD | 1 |
| Rivkin, SE | 1 |
| Von Hoff, DD | 7 |
| Alberts, DS | 4 |
| Goldsmith, MA | 1 |
| Ohnuma, T | 1 |
| Jaffrey, IH | 1 |
| Greenspan, EM | 1 |
| Holland, JF | 2 |
| Mattox, DE | 1 |
| Clark, GM | 1 |
| Balcerzak, SP | 2 |
| O'Bryan, RM | 1 |
| Oishi, N | 1 |
| Stuckey, WJ | 1 |
| Ehninger, G | 1 |
| Weible, KH | 1 |
| Heidemann, EG | 1 |
| Waller, HD | 1 |
| Falkson, G | 2 |
| Coetzer, BJ | 2 |
| Terblanche, AP | 1 |
| Muss, HB | 2 |
| Asbury, R | 1 |
| Bundy, B | 2 |
| Ehrlich, CE | 1 |
| Graham, J | 1 |
| Loesch, DM | 1 |
| Kuhn, J | 1 |
| Coltman, CA | 1 |
| Tio, F | 1 |
| Chaudhuri, TK | 1 |
| Bender, JF | 1 |
| Grillo-Lopez, AJ | 1 |
| Osborne, CK | 2 |
| Drelichman, A | 1 |
| Crawford, ED | 1 |
| Anderson, KC | 1 |
| Garnick, MB | 1 |
| Meshad, MW | 1 |
| Cohen, GI | 1 |
| Pegg, WJ | 1 |
| Frei, E | 1 |
| Israel, M | 1 |
| Modest, E | 1 |
| Canellos, GP | 1 |
| Bedikian, AY | 1 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Wynert, WR | 1 |
| Harvey, HA | 1 |
| Lipton, A | 1 |
| Schweitzer, J | 1 |
| White, DS | 1 |
| Stewart, JA | 1 |
| McCormack, JJ | 1 |
| Krakoff, IH | 1 |
| Cowan, JD | 2 |
| McDonald, B | 1 |
| Talley, RW | 1 |
| McCracken, JD | 1 |
| Chen, T | 1 |
| Piccart, M | 1 |
| Rozencweig, M | 1 |
| Abele, R | 1 |
| Cumps, E | 1 |
| Dodion, P | 1 |
| Dupont, D | 1 |
| Kisner, D | 1 |
| Kenis, Y | 1 |
| Griffith, KS | 1 |
| Goodman, GE | 1 |
| Herman, TS | 1 |
| Murray, E | 1 |
| Nicoletto, MO | 1 |
| Padrini, R | 1 |
| Koussis, H | 1 |
| Rosabian, A | 1 |
| Aversa, S | 1 |
| Endrizzi, L | 1 |
| Azzoni, P | 1 |
| Palumbo, M | 1 |
| Fiorentino, MV | 1 |
| Lévi, F | 1 |
| Tampellini, M | 1 |
| Metzger, G | 1 |
| Bizi, E | 1 |
| Lemaigre, G | 1 |
| Hallek, M | 1 |
| Colleoni, M | 1 |
| Buzzoni, R | 1 |
| Bajetta, E | 1 |
| Bochicchio, AM | 1 |
| Bartoli, C | 1 |
| Audisio, R | 1 |
| Bonfanti, G | 1 |
| Nolè, F | 1 |
| Carmo-Pereira, J | 2 |
| Costa, FO | 2 |
| Henriques, E | 2 |
| Beuzeboc, P | 1 |
| Pierga, JY | 1 |
| Lyonnet, DS | 1 |
| Couturier, J | 1 |
| Pouillart, P | 1 |
| Nel, JS | 1 |
| Falkson, CI | 1 |
| Edan, G | 1 |
| Miller, D | 1 |
| Clanet, M | 1 |
| Confavreux, C | 1 |
| Lyon-Caen, O | 1 |
| Lubetzki, C | 1 |
| Brochet, B | 1 |
| Berry, I | 1 |
| Rolland, Y | 1 |
| Froment, JC | 1 |
| Cabanis, E | 1 |
| Iba-Zizen, MT | 1 |
| Gandon, JM | 1 |
| Lai, HM | 1 |
| Moseley, I | 1 |
| Sabouraud, O | 1 |
| Ingle, JN | 1 |
| Kardinal, CG | 1 |
| Suman, VJ | 1 |
| Veeder, MH | 1 |
| Schaefer, PL | 1 |
| Kirschling, RJ | 1 |
| Mailliard, JA | 1 |
| Wang, WS | 2 |
| Tzeng, CH | 1 |
| Chiou, TJ | 2 |
| Liu, JH | 2 |
| Hsieh, RK | 2 |
| Yen, CC | 2 |
| Chen, PM | 2 |
| Tung, SL | 1 |
| Tallman, MS | 1 |
| Lee, S | 1 |
| Sikic, BI | 1 |
| Paietta, E | 1 |
| Wiernik, PH | 1 |
| Bennett, JM | 1 |
| Rowe, JM | 1 |
| Joseph, CD | 1 |
| Praveenkumar, V | 1 |
| Kuttan, G | 1 |
| Kuttan, R | 1 |
| Delozier, T | 1 |
| Vernhes, JC | 1 |
| Aitini, E | 1 |
| Cavazzini, G | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Rivera, A | 1 |
| Togliani, B | 1 |
| Di Marco, A | 1 |
| Smerieri, F | 1 |
| Muhonen, TT | 1 |
| Wiklund, TA | 1 |
| Blomqvist, CP | 1 |
| Pyrhönen, SO | 1 |
| Kimura, F | 1 |
| Takemura, Y | 1 |
| Ohtsuki, T | 1 |
| Mizukami, H | 1 |
| Takagi, S | 1 |
| Yamamoto, K | 1 |
| Nagata, N | 1 |
| Motoyoshi, K | 1 |
| ten Bokkel Huinink, WW | 1 |
| Clavel, M | 1 |
| Rodenhuis, S | 1 |
| Guastalla, JP | 1 |
| Franklin, HR | 1 |
| Koier, JJ | 1 |
| Vlasveld, T | 1 |
| Dalesio, O | 2 |
| van Tinteren, H | 1 |
| Pinedo, HM | 1 |
| Sridhar, KS | 1 |
| Hussein, AM | 1 |
| Benedetto, P | 1 |
| Waldman, SM | 1 |
| Feun, LG | 1 |
| Savaraj, N | 1 |
| Richman, SP | 1 |
| Ardalan, B | 1 |
| Desai, P | 1 |
| O'Connor, BM | 1 |
| Ziegler, P | 1 |
| Spaulding, MB | 1 |
| Gherlinzoni, F | 1 |
| Guglielmi, C | 1 |
| Mazza, P | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Tura, S | 1 |
| Arai, N | 1 |
| Hara, A | 1 |
| Umeda, M | 1 |
| Shirai, T | 1 |
| Kantarjian, HM | 1 |
| Estey, EH | 1 |
| O'Brien, S | 1 |
| Anaissie, E | 1 |
| Beran, M | 1 |
| Rios, MB | 1 |
| Keating, MJ | 1 |
| Gutterman, J | 1 |
| van Breukelen, FJ | 1 |
| Mattson, K | 1 |
| Giaccone, G | 1 |
| van Zandwijk, N | 1 |
| Planteydt, HT | 1 |
| Kirkpatrick, A | 1 |
| Gasparini, G | 1 |
| Dal Fior, S | 1 |
| Pozza, F | 1 |
| Panizzoni, GA | 1 |
| Favretto, S | 1 |
| Kreisle, WH | 1 |
| List, AF | 1 |
| McCloskey, T | 1 |
| Plezia, P | 1 |
| Peng, YM | 1 |
| George, M | 1 |
| Samonigg, H | 1 |
| Stöger, H | 1 |
| Kasparek, AK | 1 |
| Schmid, M | 1 |
| Dusleag, J | 1 |
| Pfeiffer, K | 1 |
| Smola, M | 1 |
| Steindorfer, P | 1 |
| Lechner, P | 1 |
| Gao, HR | 1 |
| Yoshida, T | 1 |
| Okazaki, N | 1 |
| Yoshino, M | 1 |
| Ohkura, H | 1 |
| Miyamoto, K | 1 |
| Shimada, Y | 1 |
| Dunk, AA | 1 |
| Scott, SC | 1 |
| Johnson, PJ | 1 |
| Melia, W | 1 |
| Lok, AS | 1 |
| Murray-Lyon, I | 1 |
| Williams, R | 1 |
| Thomas, HC | 1 |
| Martoni, A | 2 |
| Rani, P | 1 |
| Ercolino, L | 1 |
| Canova, N | 1 |
| Pannuti, F | 2 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Bhardwaj, S | 1 |
| Paciucci, PA | 1 |
| Wilfinger, CL | 1 |
| Strashun, A | 1 |
| Cantinho-Lopes, MG | 1 |
| Godinho, F | 1 |
| Sales-Luis, A | 1 |
| Suga, J | 1 |
| Saijo, N | 1 |
| Shinkai, T | 1 |
| Eguchi, K | 1 |
| Sasaki, Y | 1 |
| Sakurai, M | 1 |
| Sano, T | 1 |
| Tamura, T | 1 |
| Hoshi, A | 1 |
| Neidhart, JA | 1 |
| Constanzi, JJ | 1 |
| Vaughn, CB | 1 |
| Allegra, JC | 1 |
| Woodcock, T | 1 |
| Woolf, S | 1 |
| Henderson, IC | 1 |
| Bryan, S | 1 |
| Reisman, A | 1 |
| Dukart, G | 1 |
| Sutton, GP | 1 |
| Hatch, KD | 1 |
| Perren, TJ | 1 |
| Blackledge, G | 1 |
| Mould, JJ | 1 |
| Chetiyawardana, AD | 1 |
| Morrison, M | 1 |
| Hancock, A | 1 |
| Taylor, SA | 1 |
| Tranum, BT | 1 |
| Costanzi, JJ | 1 |
| Metz, R | 1 |
| Delgado, M | 1 |
| Keiling, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Misset, JL | 1 |
| Grimbert, J | 1 |
| Mathe, G | 1 |
| Periti, P | 1 |
| della Cuna, GR | 1 |
| Mazzei, T | 1 |
| Preti, P | 1 |
| Mini, E | 1 |
| van Oosterom, AT | 1 |
| Fosså, SD | 1 |
| Mulder, JH | 1 |
| Calciati, A | 1 |
| de Pauw, M | 1 |
| Sylvester, R | 1 |
| Bonnet, JD | 1 |
| Stephens, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Solid Tumor[NCT02043756] | Phase 1 | 20 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Phase 1-2 Study of PLM60 in Patients With Peripheral T-Cell Lymphoma[NCT03553914] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2021-01-31 | Withdrawn (stopped due to IND Inactive Status) | ||
| Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders[NCT02021825] | Phase 4 | 50 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for mitoxantrone and Leukocytopenia
| Article | Year |
|---|---|
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Topics: Cardiomyopathies; Disease Progression; Epidemiologic Studies; Humans; Immunosuppressive Agents; Infe | 2019 |
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
Topics: Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B | 1996 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
[Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
Topics: Alopecia; Doxorubicin; Epirubicin; Heart; Humans; Leukopenia; Mitoxantrone; Nausea; Randomized Contr | 1991 |
21 trials available for mitoxantrone and Leukocytopenia
| Article | Year |
|---|---|
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2014 |
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2014 |
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2014 |
Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2014 |
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; D | 2009 |
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Pr | 2004 |
Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer.
Topics: Adult; Aged; CA-125 Antigen; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Cystade | 1995 |
A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule | 1993 |
Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1993 |
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Topics: Adjuvants, Immunologic; Adult; Alopecia; Amenorrhea; Drug Therapy, Combination; Female; Follow-Up St | 1997 |
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1997 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; C | 1999 |
A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1992 |
Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer.
Topics: Breast Neoplasms; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukopenia; Mito | 1992 |
Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Ev | 1991 |
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1990 |
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation | 1991 |
A phase I trial of 14-day continuous intravenous infusion mitoxantrone.
Topics: Adult; Aged; Diarrhea; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Infusions, Intrav | 1991 |
[Phase II clinical trial on mitoxantrone].
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Drug Evaluation; Female; Humans; Leukopenia; Lymphoma, No | 1989 |
Intensive single-agent mitoxantrone for metastatic breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Humans; Leukopenia; Mitoxantrone; N | 1988 |
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica | 1985 |
A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Cardiac Output; Clinical Trial | 1985 |
Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality T | 1985 |
40 other studies available for mitoxantrone and Leukocytopenia
| Article | Year |
|---|---|
Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.
Topics: Adult; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mit | 2011 |
Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2006 |
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study.
Topics: Anthraquinones; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Mitoxantrone; Ovarian Neop | 1984 |
Phase I study of mitoxantrone on a daily X 5 schedule.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Mal | 1984 |
Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Femal | 1984 |
Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1984 |
Phase II trial of mitoxantrone in patients with primary liver cancer.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leu | 1984 |
Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Anthraquinones; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopen | 1984 |
Phase I investigation of ametantrone.
Topics: Aged; Anthraquinones; Arrhythmias, Cardiac; Bone Marrow; Dose-Response Relationship, Drug; Drug Eval | 1983 |
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Anthraquinones; Drug Evaluation; Humans; Leukopenia; Male; Middle Aged; Mitoxa | 1983 |
Phase I trial of mitoxantrone by 24-hour continuous infusion.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child; Child, Preschool; Drug Evalua | 1983 |
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukocyte Count | 1983 |
Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; H | 1982 |
Clinical and clinical pharmacologic studies of mitoxantrone.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; F | 1982 |
Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluati | 1982 |
Phase I clinical trial with ametantrone (NSC-287513).
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluatio | 1981 |
Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.
Topics: Aged; Anthracenes; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle | 1980 |
Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics.
Topics: Analysis of Variance; Animals; Chi-Square Distribution; Chronobiology Phenomena; Circadian Rhythm; C | 1994 |
Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide | 1996 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding | 1999 |
Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe | 1992 |
Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme- | 1992 |
Phase II trial of mitoxantrone in head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Dose-Response R | 1991 |
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea | 1991 |
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fever; Granulocyte-Macrophage Col | 1992 |
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Mitoxantr | 1991 |
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1991 |
Phase II trial of mitoxantrone in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Leukopenia; Liver Neoplasms; Male; | 1988 |
Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Hepatocellular; Child; Drug Evaluation; Female; Heart Diseas | 1985 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Hu | 1988 |
Phase II study of mitoxantrone in patients with non-small cell lung cancer.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Heart; Humans; Leukopenia; Lun | 1986 |
Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1985 |
Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Pare | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |
Phase II studies of mitoxantrone in patients with primary liver cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; Leukopenia; Liver Neopl | 1985 |
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Mal | 1985 |
Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
Topics: Anthraquinones; Drug Evaluation; Humans; Leukopenia; Mitoxantrone; Multiple Myeloma | 1985 |